A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TS-161 Administered Orally to Healthy Male and Female Participants
Latest Information Update: 02 Mar 2020
At a glance
- Drugs TS 161 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Taisho Pharmaceutical
Most Recent Events
- 26 Feb 2020 Status changed from recruiting to completed.
- 07 Jun 2019 Status changed from not yet recruiting to recruiting.
- 29 Apr 2019 New trial record